Acquisition
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder
Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular
Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology
Regeneron Acquires UK-Based Eye Drug Developer Oxular
Regeneron, Oxular, eye drug development, retinal therapeutics, acquisition
Novartis to Consolidate MorphoSys Acquisition with Site Closures and Layoffs
Novartis, MorphoSys, acquisition, consolidation, layoffs, site closures
Novo Holdings to Finalize $16.5B Acquisition of Catalent Following Regulatory Clearance
Novo Holdings, Catalent, Acquisition, Regulatory Clearance, Life Sciences, Pharmaceutical Development
From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics
Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry
European Commission Approves Novo Holdings’ $16.5B Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, Pharmaceutical Industry
Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, EU Approval, Pharmaceutical Services
Roche Acquires Poseida Therapeutics for Up to $1.5 Billion, Expanding Off-the-Shelf CAR-T Capabilities
Roche, Poseida Therapeutics, CAR-T therapy, off-the-shelf cell therapies, allogeneic cell therapy, biotech acquisition